Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Cosman, Felicia; B Crittenden, Daria; D Adachi, Jonathan; Binkley, Neil; Czerwinski, Edward; Ferrari, Serge; C Hofbauer, Lorenz; Lau, Edith; Michael Lewiecki, E; Miyauchi, Akimitsu; A F Zerbini, Cristiano; E Milmont, Cassandra; Chen, Li; Maddox, Judy; D Meisner, Paul; Libanati, Cesar; Grauer, Andreas

doi:10.1056/nejmoa1607948

Public

Romosozumab Treatment in Postmenopausal Women with Osteoporosis.

Published in The New England journal of medicine • Oct 20, 2016

NobleIDark:/48914/w1/20260526/CFE19B5ARecord on NobleID

Authors:

Felicia Cosman

,

Daria B Crittenden

,

Jonathan D Adachi

Abstract

BACKGROUND: Romosozumab, a monoclonal antibody that binds sclerostin, increases bone formation and decreases bone resorption. METHODS: We enrolled 7180 postmenopausal women who had a T score of -2.5 to -3.5 at the total hip or femoral neck. Patients were randomly assigned to receive subcutaneous inj...

Discussions